8-K: Mineralys Q3 2025: NDA Prep, OSA Trial Progress, Cash Boost

Mineralys Therapeutics reports Q3 2025 financial results, highlights progress towards lorundrostat NDA submission, and announces completion of Explore-OSA trial enrollment.

Summary

• Mineralys Therapeutics announced financial results for the third quarter ended September 30, 2025, and provided a corporate update.
• The company plans to submit a New Drug Application (NDA) for lorundrostat in late-2025 or Q1 2026, following pre-NDA feedback from the FDA.
• Enrollment has been completed in the Explore-OSA trial, with topline results anticipated in Q1 2026.
• Cash, cash equivalents, and investments increased significantly to $593.6 million as of September 30, 2025, compared to $198.2 million as of December 31, 2024.
• The company believes its current cash will be sufficient to fund planned clinical trials, regulatory activities, and corporate operations into 2028.
• Research and Development (R&D) expenses decreased to $31.5 million for Q3 2025 from $54.0 million for Q3 2024, primarily due to the conclusion of the lorundrostat pivotal program.
• General and Administrative (G&A) expenses increased to $9.7 million for Q3 2025 from $6.1 million for Q3 2024, driven by higher compensation and professional fees.
• Net loss for Q3 2025 was $36.9 million, a decrease from $56.3 million for Q3 2024.
• A public equity financing was completed on September 4, 2025, raising approximately $287.5 million in gross proceeds.

Sentiment

Score: 8

Explanation: The company has significantly strengthened its financial position, extended its cash runway, and made substantial progress towards regulatory submission for its lead candidate, lorundrostat, while also advancing its pipeline for additional indications. These are strong positive indicators for a clinical-stage biopharmaceutical company.

Positives

• Strong cash, cash equivalents, and investments balance of $593.6 million as of September 30, 2025, significantly up from $198.2 million at year-end 2024.
• Extended cash runway into 2028, providing financial stability for ongoing operations and development.
• NDA submission for lorundrostat is on track for late-2025/Q1 2026, indicating significant progress towards potential market entry.
• Completion of enrollment in the Explore-OSA trial, with topline results expected in Q1 2026, potentially expanding lorundrostat's market opportunity.
• Net loss decreased to $36.9 million in Q3 2025 from $56.3 million in Q3 2024.
• Successful completion of a public equity financing on September 4, 2025, which generated approximately $287.5 million in gross proceeds.

Negatives

• General and Administrative (G&A) expenses increased to $9.7 million in Q3 2025 from $6.1 million in Q3 2024, primarily due to higher compensation and professional fees.
• The company continues to incur a net loss of $36.9 million for the quarter, which is typical for a clinical-stage biopharmaceutical company.

Risks

• Topline results reported are based on preliminary analysis and may change following a more comprehensive review of the data.
• Future performance is entirely dependent on the success of lorundrostat.
• Potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies.
• Later developments with the FDA may be inconsistent with feedback from prior meetings, including whether the proposed pivotal program will support registration.
• Any delays in the FDA's review of the planned NDA submission, potentially due to government shutdowns or reductions in agency funding.
• Results of clinical trials (Advance-HTN and Launch-HTN) may not be deemed sufficient by the FDA for NDA submission or regulatory approval.
• Dependence on third parties for manufacturing, research, and clinical and nonclinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat could limit its development, regulatory approval, and/or commercialization.
• Unfavorable results from clinical trials and nonclinical studies.
• Results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results.
• Macroeconomic trends and uncertainty, including high interest rates, elevated inflation, tariffs, and the potential for economic recession.
• Ability to maintain undisrupted business operations due to any pandemic or future public health concerns.
• Regulatory developments in the United States and foreign countries.
• Reliance on an exclusive license with Mitsubishi Tanabe Pharma for intellectual property rights to develop and commercialize lorundrostat.

Future Outlook

The company anticipates submitting a New Drug Application (NDA) for lorundrostat to the FDA in late 2025 or Q1 2026. Topline results from the Explore-OSA trial are expected in Q1 2026, which could further expand lorundrostat's potential in treating hypertension patients with comorbidities. The current cash position is projected to fund operations into 2028.

Management Comments

• "We are at an exciting point in our company's history as we prepare for our NDA submission following pre-NDA feedback from the FDA last month." Jon Congleton, Chief Executive Officer.
• "Our team has developed a fulsome data package consisting of multiple clinical trials which have demonstrated a well characterized efficacy and safety profile across distinct populations with uncontrolled and resistant hypertension." Jon Congleton, Chief Executive Officer.
• "These findings for lorundrostat will provide the foundation for an NDA submission which we anticipate submitting near the end of 2025 or during the first quarter of 2026." Jon Congleton, Chief Executive Officer.
• "We continue to evaluate lorundrostat's use in prevalent comorbidities of hypertension, for which normalizing aldosterone production may result in meaningful clinical benefit." Jon Congleton, Chief Executive Officer.
• "Following positive topline data from our Phase 2 Explore-CKD trial, demonstrating successful results in the OSA patient population in our Phase 2 Explore-OSA trial would continue to expand the opportunity for lorundrostat in treating hypertension patients." Jon Congleton, Chief Executive Officer.

Industry Context

Mineralys Therapeutics operates in the biopharmaceutical sector, focusing on hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). These conditions represent significant unmet medical needs, with less than 50% of hypertension patients achieving their blood pressure goals with existing medications. Dysregulated aldosterone, which lorundrostat targets, is a key factor in approximately 30% of hypertensive patients. The high prevalence of CKD (1-in-7 U.S. adults) and OSA (almost one billion people globally) underscores the large market potential for a novel therapeutic approach like lorundrostat, especially given the strong link between these conditions and hypertension.

Stakeholder Impact

• Shareholders: Positive impact due to a significantly strengthened balance sheet, extended cash runway into 2028, and substantial progress towards NDA submission for lorundrostat, which could enhance long-term value. However, the recent equity financing has resulted in share dilution, as reflected in the increased weighted-average shares.
• Patients: Potential positive impact from the advancement of lorundrostat towards regulatory approval, offering a new therapeutic option for uncontrolled/resistant hypertension, chronic kidney disease, and obstructive sleep apnea.
• Employees: The increase in General and Administrative expenses, partly due to higher compensation and additions to headcount, suggests growth and stability in employment opportunities within the company.

Next Steps

• Submit a New Drug Application (NDA) for lorundrostat to the FDA in late-2025 or Q1 2026.
• Anticipate topline results from the Explore-OSA trial in Q1 2026.
• Continue to gather ongoing safety and efficacy data from the Transform-HTN Open-Label Extension Trial.
• Evaluate lorundrostat's use in prevalent comorbidities of hypertension.

Key Dates

Recommendation

Mineralys Therapeutics has achieved critical milestones, including a substantial capital raise that extends its cash runway into 2028, and is on the cusp of submitting its NDA for lorundrostat. The completion of enrollment for the Explore-OSA trial further expands the drug's potential. These are strong positive indicators for a clinical-stage biopharmaceutical company. However, the company remains pre-revenue, and the success of lorundrostat is entirely dependent on FDA approval and subsequent commercialization, which carries inherent risks. The recent equity financing, while necessary for funding, also resulted in share dilution. Therefore, a 'hold' recommendation is appropriate, acknowledging the significant progress and strong financial footing while remaining cautious about the remaining regulatory and commercialization hurdles.

Keywords

Mineralys Therapeutics, MLYS, lorundrostat, hypertension, obstructive sleep apnea, OSA, chronic kidney disease, CKD, aldosterone synthase inhibitor, NDA submission, clinical trials, biopharmaceutical, Q3 2025 financial results, drug development, clinical-stage